TyrNovo Overview
- Year Founded
-
2005
- Status
-
Acquired/Merged
- Latest Deal Type
-
2ndary - Private
- Latest Deal Amount
-
$1.65M
TyrNovo General Information
Description
Developer of small molecular drugs designed to treat cancer and inflammation diseases. The company's small molecular drugs are used for the treatment for several neuro degenerative conditions that result from acute events, such as stroke, traumatic brain injury, nerve agents exposure and open heart surgery, glaucoma, enabling patients to begin treatment more quickly and result in a higher likelihood of a successful treatment.
Contact Information
Website
www.tyrnovo.co.ilCorporate Office
- 8 Abba Eban Avenue
- Herzliya 46723
- Israel
Corporate Office
- 8 Abba Eban Avenue
- Herzliya 46723
- Israel
TyrNovo Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | 06-Oct-2017 | $1.65M | Completed | Generating Revenue | ||
| 4. Merger/Acquisition | 06-Oct-2017 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 19-Mar-2013 | Completed | Startup | |||
| 2. Early Stage VC | 18-Jun-2008 | $1M | $1M | Completed | Startup | |
| 1. Seed Round | Completed | Startup |
TyrNovo Patents
TyrNovo Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3236225-A1 | Isolated trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-n-(3,4,5-trihydroxy-benzyl)-thioacrylamide | Pending | 04-Nov-2021 | ||
| EP-4426278-A1 | Isolated trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-n-(3,4,5-trihydroxy-benzyl)-thioacrylamide | Pending | 04-Nov-2021 | ||
| EP-4426278-A4 | Isolated trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-n-(3,4,5-trihydroxy-benzyl)-thioacrylamide | Pending | 04-Nov-2021 | ||
| US-20240425452-A1 | Isolated trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-n-(3,4,5-trihydroxy-benzyl)-thioacrylamide | Pending | 04-Nov-2021 | ||
| WO-2023079545-A1 | Isolated trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-n-(3,4,5-trihydroxy-benzyl)-thioacrylamide | Inactive | 04-Nov-2021 | C07C327/44 |
TyrNovo Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Biomedix Incubator | Accelerator/Incubator | Minority | ||
| Gefen Biomed Investments | Venture Capital | Minority | ||
| Goldman Hirsh Partner | Corporation | Minority | ||
| Meytav Technological Incubator | Accelerator/Incubator | Minority | ||
| Orot Luces | Impact Investing | Minority |
TyrNovo FAQs
-
When was TyrNovo founded?
TyrNovo was founded in 2005.
-
Where is TyrNovo headquartered?
TyrNovo is headquartered in Herzliya, Israel.
-
What industry is TyrNovo in?
TyrNovo’s primary industry is Drug Discovery.
-
Is TyrNovo a private or public company?
TyrNovo is a Private company.
-
What is the current valuation of TyrNovo?
The current valuation of TyrNovo is .
-
What is TyrNovo’s current revenue?
The current revenue for TyrNovo is .
-
How much funding has TyrNovo raised over time?
TyrNovo has raised $1M.
-
Who are TyrNovo’s investors?
Biomedix Incubator, Gefen Biomed Investments, Goldman Hirsh Partner, Meytav Technological Incubator, and Orot Luces are 5 of 6 investors who have invested in TyrNovo.
-
When was TyrNovo acquired?
TyrNovo was acquired on 06-Oct-2017.
-
Who acquired TyrNovo?
TyrNovo was acquired by Purple Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process